Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon Corp increased its stake in Janux Therapeutics by 13.3%, owning approximately 89,370 shares valued at $2.41 million.
• Several institutional investors, including Russell Investments Group Ltd., have significantly increased their holdings in Janux Therapeutics, with hedge funds owning about 75.39% of the stock.
• Janux Therapeutics reported earnings of ($0.38) per share, exceeding the consensus estimate, and has a market cap of $1.51 billion.

Bank of New York Mellon Corp increased its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 13.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,370 shares of the company's stock after buying an additional 10,511 shares during the period. Bank of New York Mellon Corp owned 0.15% of Janux Therapeutics worth $2,413,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Janux Therapeutics during the fourth quarter valued at about $59,000. FNY Investment Advisers LLC increased its holdings in shares of Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after acquiring an additional 2,425 shares in the last quarter. Finally, KBC Group NV acquired a new position in Janux Therapeutics in the 1st quarter worth approximately $66,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Janux Therapeutics stock traded down $0.06 during trading on Friday, reaching $23.96. The company had a trading volume of 228,840 shares, compared to its average volume of 940,704. The firm's 50-day simple moving average is $24.77 and its 200 day simple moving average is $29.81. Janux Therapeutics, Inc. has a 1-year low of $22.48 and a 1-year high of $71.71. The firm has a market capitalization of $1.42 billion, a PE ratio of -17.62 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $91.89.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.